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ABSTRACT 
Introduction: In the last two decades, there has been strong evidence supporting 
the use of noninvasive ventilation (NIV) in COPD cases. While there are advocates in 
favor of the use of NIV in patients presented with acute hypoxemic respiratory failure 
(AHRF) non-related to COPD nor chest trauma, efficacy of NIV in these cases is still 
heatedly debated in the medical research field. 
Objective: To critically assess the existing scientific evidence regarding efficacy 
of NIV as an adjunct therapy, the endotracheal intubation rate, intensive care and hospital 
length of stay, fatal complications, and mortality rate in patients presented with AHRF in 
non-COPD, non-trauma situations. 
Data Source: A search of PubMed, MEDLINE database from 1990 to 2010, 
Cochrane Library, and EMBASE from 1990 to 2010 were also conducted.  
Study Selection: Randomized controlled trials (n=11) that assessed the efficacy of 
NIV in patient with AHRF not related to COPD nor trauma, in addition to various cohort 
studies, observational studies, and some selective conference proceedings that are 
considered potentially relevant to the topic. 
Results: The use of NIV showed a statistically significant decrease in intubation 
and mortality rates in patients with immunosuppression who developed AHRF. There 
were also encouraging results in patients who underwent lung resection, and post-
abdominal surgical procedures who received NIV to treat AHRF.  
 vi 
 
Conclusion: This systematic review of a number of RCTs suggests that the use of 
NIV decreases the need for endotracheal intubation, fatal complications, and mortality 
rate. However, due to the diversity of study population, there is a great need for more 
specific trials on less heterogeneous patients with AHRF. 
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CHAPTER Ι: BACKGROUND 
What Is Acute Hypoxemic Respiratory Failure? 
Acute hypoxemic respiratory failure (AHRF) is severe arterial hypoxemia (low 
oxygenation in arterial blood) that does not respond to supplemental oxygen provided. It 
is caused by intrapulmonary shunting of blood (i.e. the availability of perfusion without 
ventilation) secondary to collapsed or fluid-filling air sacs (alveoli). Symptoms include 
dyspnea (shortness of breath) and tachypnea (abnormally rapid breathing). AHRF can be 
diagnosed by obtaining arterial blood gas samples (ABG) and chest radiography. 
Treatment usually requires mechanical ventilation whether invasive or noninvasive 
(Beers, Porter, Jones, Kaplan, & Berkwits, 2006).  
Noninvasive ventilation (NIV) is the delivery of mechanical ventilation without 
using an invasive artificial airway for the management of acute respiratory failure caused 
by various etiologies. 
 
Historical Overview 
NIV was first introduced in the early 20th century in the form of negative pressure 
ventilation in which a patient is placed in a large metal cylinder (iron lung), which 
encases the patient, who lay on his/her back on a mattress with the head protruding 
through an air-tight rubber neck seal (see Figure 1). It was widely used during the polio 
epidemics in the 1900s. The bulk and lack of portability of early tank ventilators 
stimulated the development of more portable negative pressure devices, including the 
12 
 
 
 
chest cuirass (see Figure 2) or “shell” ventilator and raincoat (or wrap) ventilator. The 
first cuirass, developed in 1876 by Ignez von Hauke in Austria, consisted of an iron shell 
covering the anterior part of the thorax with an air-filled rubber edge that created a tight 
seal around the chest (Mehta & Hill, 2001). 
 
  
 
Figure 1. “Iron Lung” is a well-known negative pressure ventilator. Retrieved from: 
http://colgurchemistry.com/Science9/Biology/iron%20lung%202.jpg  
  
 
  
 
Figure 2. “Chest Cuirass” is another type of negative pressure ventilator. Retrieved from 
United Hayek: http://nivusers.tripod.com/psfolder/Hayek2.jpg  
  
 
Prior to 1950, invasive positive pressure ventilation was exclusively used for the 
delivery of anesthesia during surgical procedures. However, in 1952 in Copenhagen, 
Denmark, and during the peak outbreak of the polio epidemic, and due to the 
overwhelming number of patients who required mechanical ventilation, there was a 
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massive shortage of negative pressure machines. At that point, positive pressure 
ventilation was first deployed to treat patients outside the anesthesia departments and the 
survival rates were much better with the positive pressure ventilation than with the 
negative pressure ventilation. That success during the difficult epidemic caused clinicians 
to switch to invasive positive pressure ventilation supported by the first use of intensive 
care units (ICUs) and by the less expensive, and user-friendly ventilators. Invasive 
ventilation delivered via endotracheal tube then became the first choice method to 
provide mechanical ventilation to patients with acute respiratory insufficiency (Mehta & 
Hill, 2001). 
 
Reemergence of Noninvasive Ventilation 
Because of the major complications associated with the use of invasive positive 
pressure ventilation, the practice of using NIV has increased to avoid such complications. 
Although invasive positive pressure ventilation is practically reliable in ensuring effective 
alveolar ventilation, endotracheal intubation involves serious risks of adverse 
complications: during the process of insertion or removal of the endotracheal tube; during 
the ventilation application such as barotrauma (i.e., airway injury due to excessive 
pressure); or those caused by the accidental loss of artificial airways; the bypassing of the 
patient’s natural upper airway filtering and humidification mechanisms (Pingleton, 1988). 
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Types of Noninvasive Ventilation 
NIV comes in two forms, noninvasive positive pressure ventilation (NIPPV) and 
continuous positive airway pressure (CPAP). NIPPV is a combination of inspiratory 
pressure support (also known as inspiratory positive airway pressure [IPAP]) plus 
positive end expiratory pressure (PEEP) (also known as expiratory positive airway 
pressure [EPAP]) delivered to the patient via a mask interface. Biphasic positive airway 
pressure (BiPAP1) (Respironics, Murrayville, PA) (see Figures 3 and 4), Bilevel, and 
noninvasive pressure support ventilation (NIPSV) are also used to describe NIPPV. 
CPAP provides a baseline constant positive airway pressure throughout inspiration and 
expiration, whereas BIPAP provides two levels of pressure: IPAP during inspiration and 
EPAP during expiration phase. 
 
  
 
Figure 3.  Nasal NIV Mask. Retrieved from: 
www.aic.cuhk.edu.hk/web8/NIV%20masks.htm 
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Figure 4.  Respironics Bipap-Vision with full face mask. Retrieved from 
Respironics.com:  www.healthcare.philips.com/main/products/Hospital_ 
Respiratory/Products/Noninvasive_ventilation/respironics_bipap_vision.wpd 
  
 
Golden Age of Noninvasive Ventilation 
Over the last two decades, there has been tremendous development in the field of 
NIV. In the 1980s, CPAP was delivered via face mask to treat sleep apnea. Later, volume 
and pressure-control were used to treat cases of chest wall deformity diseases, 
neuromuscular respiratory disorders, and acute respiratory failure (ARF) (Benditt, 2009). 
The implementation of noninvasive positive pressure ventilation (NIV) as a first-
line treatment in selected cases of acute respiratory failure is considered the single most 
important progress in the field of mechanical ventilation in the past two decades. In this 
review, NIV will be defined as the application of NIV, most commonly in the form of 
BiPAP, which provides pressure support in addition to positive end expiratory pressure 
(PEEP), and the other form is continuous positive airway pressure (CPAP), which is the 
equivalence of PEEP alone. It differs from BiPAP by having no added ventilatory support 
during the inspiratory cycle (Elliott, Steven, Phillips, & Branthwaite, 1990; Meduri et al., 
1991). 
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CHAPTER ΙΙ: INTRODUCTION 
Strong evidence involving several randomized controlled trials (RCTs) supports 
the use of NIV as an adjunct to standard therapy for the management of acute 
exacerbation of chronic obstructive pulmonary disease (COPD) particularly when used in 
early phases of the disease (Keenan, Powers, McCormack et al., 2002; Ram, Picot, 
Lightowler, & Wedzicha, 2004). However, evidence supporting the efficacy of NIV in 
patients with hypoxemic respiratory failure due to causes other than COPD is still 
debated and has produced conflicting results (Hill, Brennan, Garpestad, & Nava, 2007). 
The aim of this study is to conduct a systematic review of RCTs in the medical 
literature of patients with AHRF unrelated to exacerbation of COPD and chest trauma to 
assess the efficacy of NIV when combined with the usual medical care (UMC) as 
compared to the UMC alone. The main outcome measures are endotracheal intubation, 
ICU and hospital length of stay, complications, and mortality rate. 
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CHAPTER ΙΙΙ: METHOD & PROCEDURES 
Search Strategy 
A search of PubMed using the terms “non-invasive ventilation”, “noninvasive 
ventilation”, “non-invasive positive pressure ventilation”, “BiPAP”, and “CPAP” was 
conducted. Literature searches on NIV in MEDLINE from 1990 to 2010, Cochrane 
database, EMBASE from 1990 to 2010 were also conducted. In this review, the focus is 
limited to RCTs only (see Figure 4), and included other articles in the background and the 
introduction. All of the RCTs are available in full texts using the Albertson Library, 
Boise State University website (http://library.boisestate.edu/). 
 
Selection Criteria 
The following criteria were used to select articles: 
1.   Study design was a randomized controlled trial. 
2.   Study population consisted of a majority of patients (>60%) with acute 
hypoxemic respiratory failure not associated with an exacerbation of COPD 
and not requiring immediate ventilatory assistance. 
3.   The intervention included noninvasive ventilation (NIV) plus usual medical 
care (UMC) vs. UMC alone. 
4.   Outcomes included the need for endotracheal intubation, length of ICU or 
hospital stay, or ICU and/or hospital mortality. 
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Study Selection 
Initial electronic searches identified 315 studies as potentially relevant to the 
topic. Of these, studies were excluded for the following reasons: 
1. They were not randomized controlled trials or did not evaluate noninvasive 
ventilation (n = 232). 
2. The patients did not have acute hypoxemic respiratory failure or the study 
population was mixed and patients with acute hypoxemic respiratory failure 
were not reported separately (n = 72). 
 The remainder, a total of eleven randomized controlled trials, all fully published, 
met the set selection criteria (see Figure 5, Table1). 
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Figure 5. Flow diagram of trial selection process for this systematic review 
  
  
(232) trials were excluded as 
not relevant or as not 
controlled trials. 
(83) Trials were retrieved 
for more detailed 
evaluation. (72) Trials were excluded because:  
Non-hypoxemic respiratory 
failure (63), Used different 
outcomes that didn’t meet 
criteria (9). 
(11) Trials were included in 
the review. 
Number of trials with 
respect to Outcomes used: 
Endotracheal intubation (11) 
Complications (7) 
ICU Length of Stay (9) 
Hospital Length of Stay (8) 
Mortality (11) 
 
 
 
 
 
315 studies were 
identified as potentially 
relevant to the topic. 
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Table 1.  
RCTs Included in this Review 
Study, year 
(No. of 
Participants) 
Age 
(Yrs) 
Gender 
M/F 
Disease Sample 
size 
Informed 
Consents 
Obtained 
1-Wysocki et 
al., 1995 
(n=41) 
 
NIV=64±18 
UMC= 
62±11 
NIV= 12/9 
UMC=12/8 
 
ARF (no COPD) 
PaCO2>45 (n=17) 
PaCO2≤45 (n=24) 
NIV=21 
UMC=20 
yes 
2- Confalonieri 
et al., 1999 
(n=56) 
 
NIV=66±14 
UMC= 
61±21 
NIV= 
23/5 
UMC= 
17/11 
CAP+ARF (n=23), 
AHRF (n=33)* 
NIV=28 
UMC=28 
yes 
3- Antonelli et 
al., 2000. 
(n=40) 
 
NIV=45 
UMC= 
44 
NIV; 
13/7 
UMC= 
12/8 
ARF solid organ 
transplantation 
NIV=20 
UMC=20 
yes 
4- Delclaux et 
al., 2000. 
(n=123) 
 
NIV= 
62 
UMC= 
61 
NIV= 
38/24 
UMC= 
40/21 
ALI/ARDS NIV=62 
UMC=61 
yes 
5-Auriant et al., 
2001. (n=48) 
 
NIV=58.9±10 
UMC= 
63±9 
NR AHRF post-lung 
resection 
NIV=24 
UMC=24 
yes 
6-Hilbert et al., 
2001. (n=52) 
NIV=48±14 
UMC= 
50±12 
NIV= 
18/8 
UMC= 
19/7 
 
AHRF-
immunosuppressed 
NIV=26 
UMC=26 
yes 
7-Keenan et al., 
2002. (n=81). 
NIV=68.3 
(13.1) 
UMC= 
68.6 
(12.4) 
NR ARF,  post-
extubation AHRF 
NIV=39 
UMC=42 
yes 
Table 1 continues 
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Table 1 (continued) 
Study, year 
(No. of 
Participants) 
Age 
(Yrs) 
Gender 
M/F 
Disease Sample 
size 
Informed 
Consents 
Obtained 
8- Ferrer et al., 
2003. (n=105) 
NIV=61±17 
UMC= 
62±18 
NIV= 
30/32 
UMC = 
28/26 
 
AHRF NIV=51 
UMC=54 
yes 
9-L’Her et al., 
2004. (n=89) 
NIV= 
84±6 
UMC= 
84±6 
NIV= 
18/28 
UMC = 
19/24 
ACPE Elderly 
(>75 yrs old 
NIV=43 
UMC=46 
yes 
10-Squadrone 
et al., 
2005. (n=209) 
NIV= 
65(10) 
UMC= 
66(9) 
NIV= 
71/34 
UMC = 
64/40 
AHRF Post-
operative 
NIV=105 
UMC=104 
yes 
11-Gray et al., 
2008. (n=1069) 
NIV= 
77±10 
UMC= 
79±9 
NIV= 
393/309 
UMC= 
213/154 
 
ACPE NIV=702 
UMC=367 
yes 
  
NIV: noninvasive ventilation; UMC: usual medical care; ARF: acute respiratory failure; 
AHRF: acute hypoxemic respiratory failure; CAP: community acquired pneumonia; 
ACPE: acute cardiogenic pulmonary edema; ALI: acute lung injury. 
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CHAPTER IV: RESULTS 
Study Description 
Studies included in this review involve an international experience, as they 
included data from five different countries (France 1, 4, 5, 6 & 9; Italy 2, 3 & 10; Spain 
8; Canada 7; and the United Kingdom 11). Five studies involved multiple center trials (2, 
4, 8, 10 & 11). Patient populations with hypoxemic respiratory failure enrolled in these 
11 RCTs were diverse. Two trials focused on immunocompromised patients (3, 6), two 
on acute cardiogenic pulmonary edema (ACPE) patients (9, 11), one on post-lung 
resection surgery patients (5), one on community-acquired pneumonia (CAP) (2), one on 
post-extubation respiratory failure (7), one on acute lung injury (ALI) (4), one study on 
post-abdominal surgery (10), and two on more heterogeneous groups of patients (1, 8) 
(see Table 1). 
 
Study Results 
Wysocki et al.   Total of 41 patients with non-COPD ARF were included in this 
RCT between July 1990 and October 1992.  Twenty were randomly assigned for UMC, 
and twenty one were assigned for NIV treatment. Fourteen of the 20 patients (70%) who 
received UMC alone were endotracheal intubated versus 13 of the 21 patients (62%) who 
were treated with NIV in addition to UMC  (P=0.88) (Table 2). The ICU length of stay 
was 25 ± 23 days in the case of UMC patients and 17 ± 19 days in the case of NIV 
patients (P=0.16). In the UMC group, 10 of the 20 patients (50%) died, and in the NIV 
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group, 7 of the 21 (33%) patients died (P=0.46) (Table 2). In this study population, the 
authors performed a subgroup analysis between those patients who had hypercapnea 
PaCO2> 45 mm Hg, and the second subgroup that had their PaCO2≤45 mm Hg. 
Endotracheal intubation was required in all 6 hypercapnic patients (100%) who received 
UMC, while only 4 of the 11 hypercapnic patients (36%) required intubation in the NIV 
group (P=0.02). The ICU length of stay was significantly lower in hypercapnic patients 
treated with NIV (13 ± 15 days versus 32 ± 30 days, P=0.04) and 4 of the 6 hypercapnic 
patients from UMC group died (66%), while one of the 11 hypercapnic patients (9%) 
died who received the NIV (P=0.06).  Oppositely, in the subgroup of patients with 
PaCO2≤ 45 mm Hg (n=24), there were no positive effects with the use of NIV (Table 2). 
Confalonier et al.  The study took place between November 1996 and March 
1998 and included 56 patients with community-acquired pneumonia (CAP) and ARF 
from multi-center settings. The population was divided equally, 28 to be treated with 
UMC alone and 28 with NIV intervention. Twenty-three patients had a history COPD 
and they were analyzed separately. The other non-COPD patients (n=33) were also 
analyzed separately, which is the group considered in the analysis. In the UMC group, 8 
of the 17 patients (47.1%) required endotracheal intubation while 6 of the 16 patients 
(37.5%) in the NIV group required intubation (P=0.73). In the UMC group, the ICU 
length of stay was 4.8±1.7 days versus 2.9±1.8 days in the NIV group (P=0.44). The 
overall hospital stay was 15.1±2.8 days in the UMC group versus 17.9±2.9 days in the 
NIV group (0.48). In the UMC group, 4 of the 17 patients (23.5%) died versus 6 of 16 
patients (37.5%) in the NIV group (P=0.47) (Table 2). 
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Antonelli et al. The study was conducted between December 1995 and October 
1997 and involved 40 patients who received a solid organ transplant (liver, kidney, or 
lung) and were treated in ICU for AHRF, which occurred post transplantation. There 
were 20 patients randomly assigned in each group. Fourteen patients (70%) in the UMC 
group required intubation and 4 patients (20%) in the NIV group (P = 0.002). The length 
of stay among the survivors in the ICU was better in the NIV group (5.5 days versus 9 
days in the UMC group; (P=0.03)). The mortality rate in the ICU was 10 patients (50%) 
in the UMC group versus 4 patients (20%) in the NIV group (P=0.05). Finally, serious 
fatal complications leading to death were significantly higher in the UMC group than the 
NIV group (10 vs 4; P= 0.05) (Table 2). 
Delclaux et al. Between September 1997 and January 1999, 123 adult patients 
admitted with acute respiratory insufficiency secondary to pulmonary edema were 
recruited at the medical ICUs of 6 hospitals from France, Spain, Tunisia, and Italy. One 
hundred and two (83%) patients were presented with acute lung injury (ALI) (PaO2/FIO2 
ratio ≤ 300 mm Hg), while 21(17%) were classified as having pure cardiac 
decompensation.  Patients with an underlying cardiac disease were equally distributed 
between the UMC and the CPAP groups. There were 61 patients in the UMC group 
versus 60 patients in the CPAP plus UMC group.  No significant differences were found 
between the two treatment groups for any of the clinical outcome measures studied, 
including rate of endotracheal intubation, length of hospital stay, and hospital mortality 
rate. However, the complications were more common in the CPAP group: 18 (29%) 
versus 6 (10%) in the UMC group (P = 0.01) (Table 2).  
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Auriant et al. Between May 1999 and July 2000, 48 patients with AHRF 
following lung resection were enrolled in this RCT. The indication for lung resection was 
lung cancer for all patients in this population. All the patients were extubated in the 
operating room after surgery. The study population was randomly assigned to UMC 
alone (n=24) and NIV plus UMC (n=24). In the UMC alone group, 12 of the 24 patients 
(50%) required intubation versus only five of the 24 patients (20.8%) in the NIV group (P 
=0.035) (Table 2). Nine patients in the UMC group (37.5%) died, versus only three 
(12.5%) in the NIV group (P=0.045).The ICU and hospital length of stay were similar in 
the two groups. There was no death in either group after hospital discharge, so that in 
both groups, in-hospital mortality was equal to 120-d mortality (Table 2). 
Hilbert et al. The study took place between May 1, 1998 and December 31, 1999. 
A total of 52 patients with immunosuppression were admitted to the ICU with AHRF 
associated with pulmonary infiltrates and fever. There were 26 patients in the UMC 
group and 26 in the NIV group. Twenty patients of the 26 (77%) in the UMC group 
required endotracheal intubation versus 12 patients of the 26 (46%) in the NIV group 
(P=0.03). In the UMC group, 18 of the 26 (69%) died in the ICU versus 10 of the 26 
(38%) in the NIV group (P= 0.03). The ICU length of stay among survivors was 9±4 days 
in the UMC group versus 7±3 days in the NIV group. In the UMC group, hospital 
mortality was 21 of the 26 (81%) versus 13 of the 26 (50%) in the NIV group (P= 0.02) 
(see Table 2). 
Keenan et al. The study was conducted between August 1, 1996 and October 31, 
1999. Eighty-one patients who required ventilator support for more than 48 hours, or had 
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a history of either congestive heart failure or chronic lung disease, and developed 
respiratory distress were randomly assigned to this study (42 patients in the UMC group 
and 39 patients in the NIV group). There was no statistically significant difference in the 
reintubation rate between the UMC group and the NIV group. In the UMC group, 29 of 
the 42 (69%) patients required reintubation versus 28 of the 39 (72%) patients in the NIV 
group (P=0.79). The ICU length of stay was 19.4 days in the UMC group and 15.1 days 
in the NIV group (P=0.32). The UMC group had 29.8 days hospital stay, whereas the 
NIV group had 32.2 days (P=0.69). Both groups had the same mortality rate: 29 of the 42 
(69%) in the UMC died versus 27 of the 39 in the NIV group (69%) (P=0.99) (Table 2). 
Ferrer et al. This study involved 105 patients from three different ICUs 
diagnosed with severe AHRF, defined as a PaO2 less than 60 mm Hg for more than 6-8 
hours or arterial oxygen saturation via pulse oximetry (SpO2) persistently below 90% 
while breathing 50% FIO2 via Venturi mask. They were randomly assigned to both 
groups: 54 in the UMC group and 51 in the NIV group. In those who received the UMC 
alone, 28 of the 54 (52%) required endotracheal intubation while only 13 of 51 (25%) 
needed intubation in those who were treated with adjunct NIV (P=0.01).  In the UMC 
group, 17 patients of the 54 (31%) developed septic shock versus 6 patients of the 51 
(12%) in the NIV group (P=0.02). In the ICU, 21 patients of the 54 (39%) died in the 
UMC group versus 9 patients of the 51 (18%) in the NIV group (P=0.28) (Table 2). 
L’Her et al. The study was conducted in three different emergency departments 
(EDs) and involved a total of 89 elderly patients (≥ 75 years) admitted to EDs with 
AHRF related to cardiogenic pulmonary edema (CPE). The population was randomly 
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assigned to receive UMC (n=46) or NIV, particularly CPAP therapy.  In the UMC group, 
14 of the 46 (30%) required intubation versus 4 patients (9%) in the NIV group. There 
were 17 (37%) patients who experienced serious complications in the UMC group versus 
4 (9%) in the NIV group. Early 48-hour mortality was significantly lower in the NIV 
group; 3 of the 43 (7%) patients died versus 11 of the 46 (24%) in the UMC group 
(P=0.017). In-hospital length of stay was 9±7 days in the UMC group versus 12±11 days 
in the NIV group (P=0.07) (Table 2). 
Squadrone et al. The study took place between June 2002 and November 2003 in 
multi-center ICUs. A total of 209 patients were randomly assigned to the study if they 
had AHRF post-elective abdominal surgery, with an arterial oxygen tension to inspiratory 
oxygen fraction (PaO2/FiO2) ≤ 300 while breathing 50% oxygen via Venturi mask, and 
had no underlying cardiac or chronic lung diseases. There were 104 patients in the UMC 
group and 105 patients in the NIV group (which used CPAP in this study). The rate of 
intubation was lower in the NIV group; only one patient (1%) of the 105 patients required 
intubation versus 10 patients (10%) in the UMC group (P=0.005). The ICU length of stay 
was 2.6 days in the UMC group versus 1.4 days in the NIV group (P=0.09). Hospital 
length of stay was almost similar in the two groups. Serious complications were 
significantly less in the NIV group: only 2 (2%) of the 105 patients in the NIV group 
developed pneumonia versus 10 (10%) of the 104 patients in the UMC group 
(P=0.02).There were no deaths (0%) among the NIV group while three (3%) patients died 
in UMC group (P=0.12) (Table 2). 
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Gray et al.  This is a multi-center study conducted in 26 emergency departments 
in district and regional hospitals in the United Kingdom between July 2003 and April 
2007. A total of 1069 patients were assigned to a UMC group (367 patients), and 702 
patients to a NIV group. There was no significant difference in one week or one month 
mortality between patients receiving the UMC and those undergoing the NIV. The 
mortality rate for one week was 9.8% in the UMC group and 9.5% in the NIV group (P = 
0.87). The mortality rate for one month was 16.4% in the UMC group and 15.2% in the 
NIV group (P = 0.64) (Table 2). 
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Table 2. 
RCTs Results 
Study, year 
(No. of 
Participants) 
ETI & MV 
(%) 
UMC vs. 
NIV 
ICU LOS (days) 
UMC vs. NIV 
Hosp. 
LOS 
(days) 
UMC vs. 
NIV 
Complications 
UMC vs. NIV 
Mortality (%) 
UMC vs. NIV 
1-Wysocki et 
al.,1995 (n=41) 
PaCO2>45 
(n=17) 
 
PaCO2≤45 
(n=24) 
14(70) vs 
13(62) p= 
0.88 
PaCO2>45: 6 
(100) vs 4 
(36) p=0.02 
PaCO2≤ 45: 
8 (57) vs 9 
(90) p=0.19 
 
25±23 vs17±19 p=0.16 
PaCO2>32±30vs13+ 15 
p=0.04 
PaCO2≤ 45; 22 ±20 vs 
22 ± 22 
P = 0.83 
NR NR 10 (50)vs 7(33) 
P=0.46 
PaCO2>45:4(66)vs 
1(9) p=0.06 
PaCO2≤45: 
6(43) vs 6 (60) 
P = 0.76 
2- Confalonieri 
et al., 1999 
(n=56) 
AHRF (n=33) 
considered 
 
8 (47.1)  vs 6 
(37.5) 
P = 0.73 
4.8±1.7  
  vs 
2.9±1.8 
P=0.44 
15.1±2.8 
  vs 
17.9±2.9 
P= 0.48 
NR 4(23.5)  vs 6(37.5) 
P=0.17 
3- Antonelli et 
al., 2000. (n=40) 
 
14(70)  vs 
4(20) 
P= 0.002 
9 vs 5.5 
P=0.03 
NR 10(50)  vs 4(20) 
P= 0.05 
10(50) vs 4(20) 
P= 0.05 icu 
11(55)  vs 7(35) 
P= 0.17hosp 
4- Delclaux et 
al., 2000. 
(n=123) 
 
24(39) vs 
21(34) 
P=0.53 
12 vs 15 
P=0.43 
32 vs 
30.5 
P=0.77 
6(10) vs 18(29) 
P= 0.01 ↑ 
18(29) vs 19(31) 
P= 0.24 
5-Auriant et al., 
2001. (n=48) 
 
12(50) vs 
5(20.8) 
P=0.035 
14 vs 16.65 
P= 0.52 
22.8 vs 
27.1 
P= 0.61 
NR 9(37.5) vs  3(12.5) 
P=0.045 
6-Hilbert et al., 
2001. (n=52) 
20(77) vs  
12(46) 
P= 0.03 
10±4  vs 7±3 
P=0.06 
NR 21(81) vs  13(50) 
P=0.02 
21(81)  vs 13(50) 
P= 0.02 
Table continues 
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Table 2 (continued) 
Study, year 
(No. of 
Participants) 
ETI & MV 
(%) 
UMC vs. 
NIV 
ICU LOS (days) 
UMC vs. NIV 
Hosp. 
LOS 
(days) 
UMC vs. 
NIV 
Complications 
UMC vs. NIV 
Mortality (%) 
UMC vs. NIV 
7-Keenan et al., 
2002. (n=81). 
29(69) vs 
28(72) 
P= 0.79 
19.4 vs 15.1 
P= 0.32 
29.8 vs 
32.2 
P= 0.69 
17 (40) vs 16 
(41) 
P = 0.61 
29(69)  vs  27(69) 
P=0.99 
8- Ferrer et al., 
2003. (n=105) 
28(52) vs 
13(25) 
P= 0.01 
11.3 vs 9.6 
P=0.51 
26.8 vs 
20.7 
P=0.09 
17(31) vs 6(12) 
P= 0.028 
21(39)  vs 9(18) 
P= 0.028 
9-L’Her et al., 
2004. (n=89) 
14(30)  vs 
4(9) 
P=0.01 
NR 9 vs 12 
P=0.07 
17(37) vs 4(9)  
P=0.002 
14(30) vs 12(28) 
P= 0.8 
10-Squadrone et 
al., 
2005. (n=209) 
10(10) vs 
1(1) 
P= 0.005 
2.6 vs 1.4 
P=0.09 
17 vs 15 
P=0.10 
10(10) vs 1(2) 
P= 0.02 
3(3) vs 0(0) 
P =0.12 
11-Gray et al., 
2008. (n=1069) 
10(2.8) vs 
20(2.9) 
P=0.9 
NR 39(10.5) 
vs 
77(11.4) 
P=0.10 
148(40.5)  vs 
317(45.2) 
P= 0.15 
60(16.4) vs 107(15.2) 
P=  0.64 
ETI & MV: endotracheal intubation and mechanical ventilation; ICU: intensive care unit; 
LOS: length of stay; UMC: usual medical care; NIV: noninvasive ventilation; ARF: acute 
respiratory failure; CAP: cardiogenic pulmonary edema; AHRF: acute hypoxemic 
respiratory failure; ALI: acute lung injury; ACPE: acute cardiogenic pulmonary edema; 
NR: not recorded. 
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CHAPTER V: ANALYSIS 
The results of this systematic review of the RCTs suggest that the early 
application of NIV therapy in patients presented with acute hypoxemic respiratory failure 
decreases the likelihood of endotracheal intubation. By avoiding the endotracheal 
intubation, there is great potential in improving patient outcome. There is a reduction 
trend in the rate of endotracheal intubation, ICU length of stay, and ICU mortality in 
these RCTs (see Table 3). These results were consistent when patients with COPD were 
excluded.  
 
Immunosuppressed Patients with AHRF 
 Two of the studies in which immunosuppressed patients with AHRF who 
received NIV showed statistically significant results in terms of need of endotracheal 
intubation, rate of complications, and, most importantly, decreased mortality rates 
(Antonelli et al., 2000; Hilbert et al., 2001) (see Table 3, Figure 6). The success of the 
NIV in such cases was probably a result of the avoidance of complications associated 
with the invasive mechanical ventilation in those vulnerable populations (Hill, 2001).  
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Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) 
A study conducted on patients with ALI revealed no benefits from adding CPAP 
to the UMC in those types of cases. In addition, there were more patients from the CPAP 
group who developed significantly higher rates of adverse events (Declaux et al., 2000) 
(see Table 3, Figure 7).  This could be due to the delay of conventional mechanical 
ventilation these patients needed to improve ventilation rather than oxygenation alone. In 
a similar population, a multi-center cohort study was conducted on a total of 299 patients 
at 70 ICUs. All patients were labeled as having ALI/ARDS after excluding those who 
had COPD or CPE. Of those, 209 (70%) were intubated directly without undergoing a 
NIV trial. The remainder 90 (30%) patients underwent NIV as a first-line therapy. Fifty-
four (60%) patients in the NIV group required intubation. The overall ICU mortality was 
40% in the NIV group. However, the authors concluded that although the successful NIV 
trial had a lower mortality rate, the group who failed the NIV trial had a much higher 
mortality rate than those who were intubated initially without undergoing NIV trials 
(Demoule et al., 2006a & 2006b).  Another cohort study conducted on patients with 
ALI/ARDS used PS+ PEEP as NIV with limited tidal volume (VT of 6 ml/kg) and 
adjusted the PS and PEEP according to the patient’s need. They managed to avoid 
intubation in 54% of the NIV patients. There was a statistical significance in the ICU 
mortality rate between those who avoided intubation (6%), as compared to those who 
failed the NIV trial (53%). Hospital mortality was also significantly lower in those who 
avoided intubation (19%) as compared to 54% in the NIV failures (Antonelli et al., 2007) 
(Table 3).   
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Post-Extubation AHRF 
  Keenan and colleagues conducted a study on 81 post-extubation patients who 
developed AHRF within 48 hours post-extubation, which showed no advantages from the 
use of the NIV therapy (see Table 3, Figure 8). In addition, another RCT, which is not 
included in this review, involved 224 patients from various medical centers and went 
further into this issue: it showed that the mortality rate was higher in the NIV group than 
in the UMC group (25% versus 14%, P = 0.048) (Esteban et al., 2004). 
 
Community-Acquired Pneumonia 
 The use of the NIV did not result in significant benefits in patients who were 
presented with CAP and developed AHRF and had no underlying COPD disease 
(Confalonieri, Potena, & Carbone et al., 1999) (see Figure 9). However, the same author 
in a non-randomized clinical trial of AIDS patients presented with severe pneumocystis 
pneumonia and managed by NIV showed improvement in their outcomes as compared to 
the group who received invasive mechanical ventilation (Confalonieri, Calderini, & 
Terraciano, et al., 2002). Interestingly enough, in a RCT that involved 105 patients 
presented with AHRF from heterogeneous causes, the authors indicated a significantly 
lower intubation rate and death rate in a subgroup of 34 patients with pneumonia treated 
with NIV as compared to the UMC group (Ferrer et al., 2003) (see Table 3, Figure 9) .  
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Acute Cardiogenic Pulmonary Edema 
One of the RCTs that included 89 patients showed statistically significant 
improvements in the first 48-hour mortality, the need for intubation, and in the serious 
complications in elderly patients ≥ 75 years of age admitted to the ED with ACPE and 
treated with CPAP as compared to another group treated with the UMC (L’Her et al., 
2004; Figure 10). However, in contrast to most of the trials that were conducted on 
ACPE, a larger RCT, which had 1069 patients from various medical centers in the UK, 
despite showing that the NIV improved dyspnea and arterial blood gases (ABG) in one 
hour, there were no statistically significant differences between the NIV group and the 
UMC group, in rate of intubation and in one-week mortality rate (Gray et al., 2008) (see 
Table 3, Figure 10). A large randomized patient study, (which included 130 patients) 
from multiple EDs in Italy showed that there were improvements only in PaO2/FiO2 
ratios, but showed a reduction in hypercapnic patients and not the other patients with 
PaCO2 ≤ 45, which agreed with Gray’s conclusion (Nava et al., 2003).  On the other 
hand, Potts in his meta-analysis indicated that there is strong evidence of the efficacy of 
NIV in the treatment of ACPE (Potts, 2009). 
 
Post-Surgical AHRF 
Two RCTs were conducted on post-lung resection (Auriant et al., 2001), and the 
second assessed the efficacy of NIV to treat AHRF in patients who underwent major 
abdominal surgery (Squadrone et al., 2005). Both studies showed statistically significant 
differences in the rate of intubation.  NIV successfully treats atelectasis (collapsed lung 
units), which is very common in post-abdominal surgery. In the post-lung resection 
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study, the benefit of NIV is probably because of the presence of ACPE, which usually 
responds well to NIV therapy. Aurient et al. did not assess complications, which showed 
a significant decrease in Squadrone et al. However, there was a significant reduction in 
mortality rate in the post-lung resection surgery population, yet there was no statistically 
significant improvement in post-abdominal surgery when treated with the NIV as 
compared to the UMC (see Table 3, Figure 11).  The noticeable improvements in the 
post-abdominal surgery could be because those elective cases were not considered a high 
risk population.  
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Table 3.  
Efficacy of NIV+ UMC versus UMC Alone in This Review: 
Study, year 
(No. of 
Participants) 
Disease ETI 
& 
MV 
(%) 
 
UMC 
vs. 
NIV 
ICU 
LOS 
(days) 
 
 UMC 
vs. 
NIV 
Hosp. 
LOS 
(days) 
UMC 
vs. 
NIV 
Complications 
 
UMC vs. NIV 
Mortality 
 
UMC vs. 
NIV 
1-Wysocki et 
al.,1995 (n=41) 
 
ARF (no 
COPD) 
PaCO2>45 (n=17) 
PaCO2≤45 (n=24) 
• • NR NR • 
2- Confalonieri 
et al., 1999 
(n=56) 
 
 CAP+ARF 
(n=23), 
AHRF (n=33)* 
• • • • • 
3- Antonelli et 
al., 2000. 
(n=40) 
 
ARF solid organ 
transplantation 
↓ ↓ NR ↓ ↓ICU 
4- Delclaux et 
al., 2000. 
(n=123) 
 
ALI/ARDS • • • ↑ • 
5-Auriant et al., 
2001. (n=48) 
 
AHRF post-lung 
resection 
↓ • • NR ↓ 
6-Hilbert et al., 
2001. (n=52) 
AHRF-
immunosuppressed 
↓ ↓ NR ↓ ↓ 
7-Keenan et al., 
2002. (n=81). 
ARF, AHRF 
postextubation 
• • • • • 
Table continues 
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Table 3 (continued) 
Study, year 
(No. of 
Participants) 
Disease ETI 
& 
MV 
(%) 
 
UMC 
vs. 
NIV 
ICU 
LOS 
(days) 
 
 UMC 
vs. 
NIV 
Hosp. 
LOS 
(days) 
UMC 
vs. 
NIV 
Complications 
 
UMC vs. NIV 
Mortality 
 
UMC vs. 
NIV 
10-Squadrone 
et al., 
2005. (n=209) 
AHRF Post-
operative 
↓ • • ↓ • 
11-Gray et al., 
2008. (n=1069 
ACPE • NR • • • 
  
ETI & MV: endotracheal intubation and mechanical ventilation; ICU: intensive care unit; 
LOS: length of stay; UMC: usual medical care; NIV: noninvasive ventilation; ARF: acute 
respiratory failure; CAP: cardiogenic pulmonary edema; AHRF: acute hypoxemic 
respiratory failure; ALI: acute lung injury; ARDS: acute respiratory distress syndrome; 
ACPE: acute cardiogenic pulmonary edema; •: no significant change; ↓: significant 
decrease after the use NIV; ↑: increase after the use NIV; NR: not recorded. 
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Figure 6. Summary of the subgroup studies of patients with immunosupression who 
treated NIV or UMC, which showed a statistically significant decrease in intubation, 
complication, and mortality rate (p = 0.02, p=0.03, & p=0.05) respectively, and (p=0.03, 
p= 0.02 & p=0.02) respectively. 
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Figure 7. Summary of the subgroup study of patient populations with ALI/ARDS who 
were treated with NIV or just UMC showing no statistically significant improvement 
with worse complications in the NIV group.  
  
  
 
Figure 8. Results of the study of patients with developed AHRF post-extubation and 
either received NIV or just UMC showing no benefits from the use of NIV in this 
patients’ group. 
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Figure 9. Studies that assessed the effect of NIV as compared to UMC in patients with 
community-acquired pneumonia who did not have underlying COPD disease. 
Confalonieri et al. did not show a significant improvement in intubation nor in mortality 
rates after using NIV, unlike Ferrer at al., which showed a statistically significant 
improvement in intubation rate (p= 0.01) and mortality rate (p = 0.028). 
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Figure 10. Two studies that assess the efficacy of NIV versus UMC on acute cardiogenic 
pulmonary edema (ACPE). L’Her et al. showed a significant improvement in both 
intubation rate (p = 0.01) and complications rate (P = 0.002), but did not show a 
significant drop in the mortality rate in elderly patients with ACPE. Gray et al., which 
involved a larger study sample, didn’t show a significant improvement in intubation, 
complications, or mortality rate.  
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Figure 11. Results of the subgroup in two studies of patients presented post-lung 
resection AHRF(Auriant et al.), and post-elective abdominal surgery with AHRF, who 
were treated with NIV versus UMC, showed a statistically significant improvement in 
intubation rates (p=0.03, p=0.05). Both also showed a drop in mortality rates. In addition, 
Squadrone et al. showed a statistically significant improvement in the complications rate 
(P=0.0.2), which was not recorded in Aurient et al. 
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CHAPTER VI: CONCLUSION  
In the last few years, several randomized and non-randomized trials showed 
strong evidence of the benefit of using NIV therapy in COPD exacerbation cases. This 
researcher reviewed the literature to assess the efficacy of NIV in patients with acute 
hypoxemic respiratory failure (AHRF).  
From the analysis of the eleven RCTs that were included in this systematic 
review, the overall results suggest that the use of NIV in AHRF patients decreases the 
need for endotracheal intubation, ICU length of stay, and mortality rate. However, it is 
difficult to generalize these results on most of the AHRF cases due to the wide 
heterogeneity in the populations of these RCTs and due to small sample sizes in some of 
the trials. Some subgroups showed clear benefits from the use of NIV as compared to the 
UMC alone. This was seen in patients with immunosuppression after lung resection, and 
in patients who underwent abdominal surgery, although the study involved only elective 
procedures. Nevertheless, there was strong evidence of a significant benefit from the use 
of NIV in reducing the death rate in ACPE, regardless of the RCT in Gray’s et al. In other 
etiologies, the use of NIV showed various results.   
More focused studies that concentrate on patient groups with AHRF, with less 
heterogeneity in etiology would likely be more reliable. It is noteworthy that increased 
clinical experience with the application, patient tolerance, and selection of the most 
appropriate interface is fundamentally important (Kallet, 2009). Additionally, patient 
monitoring has an important role in improving the outcomes.  
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The use of NIV should not be a reason to delay endotracheal intubation when it is 
indicated. Competent personnel such as respiratory therapists and registered nurses in 
highly monitored clinical settings are always a critical factor for optimal use of NIV and 
to ensure patient safety.   
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